Description: Kopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
Home Page: www.kopran.com
Parijat House
Mumbai,
400018
India
Phone:
91 22 4366 1111
Officers
| Name | Title |
|---|---|
| Mr. Surendra Shrikrishna Somani B.Com. | Executive Vice Chairman & MD |
| Mr. Basant Kumar Soni | Chief Financial Officer |
| Mr. Sunil Sodhani | Company Secretary & Compliance Officer |
| Mr. Ajit Jain FCA | Chief Operating Officer |
| Ms. Vandana Somani | Director |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 18.7842 |
| Price-to-Book MRQ: | 2.1008 |
| Price-to-Sales TTM: | 1.6424 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 842 |